Comment

Filter By:

Article Type
  • Declining recruitment rates in inflammatory bowel disease (IBD) trials have resulted in calls to modify the conduct of trials in IBD in order to make them more efficient and patient centred. Here, we propose a number of potential modifications.

    • Nurulamin M. Noor
    • Miles Parkes
    • Tim Raine
    Comment
  • Pancreatic ductal adenocarcinoma (PDAC) reflects the current challenge for immuno-oncology: to develop new drugs for cancers that are resistant to current immunotherapies. Here, we argue for a need to use patients to uncover new strategies that activate anti-tumour immunity.

    • Luis A. Rojas
    • Vinod P. Balachandran
    Comment
  • The application of single-cell RNA sequencing platforms has generated notable insights into the heterogeneity underlying pancreatic ductal adenocarcinoma (PDAC), encompassing both the neoplastic compartment and the tumour microenvironment. In this Comment, we discuss the most pertinent findings gleaned from both mouse models and human PDAC samples, as well as future opportunities.

    • Jincheng Han
    • Ronald A. DePinho
    • Anirban Maitra
    Comment
  • The Association of Black Gastroenterologists and Hepatologists is a new organization that aims to improve gastrointestinal health outcomes in Black communities, foster networking and scholarship among its members, develop the pipeline of Black gastroenterologists and hepatologists, and promote health equity in the fields of gastroenterology and hepatology.

    • Pascale M. White
    • Ugonna Iroku
    • Renee L. Williams
    Comment
  • Traditionally underutilized human excreta have emerged as a rich source of digital biomarkers for disease prevention and early detection. In this Comment, we highlight the breadth of digital biomarkers that can be extracted from human excreta and their potential uses in the context of ‘precision health’.

    • Seung-min Park
    • T. Jessie Ge
    • Joseph C. Liao
    Comment
  • The popularity of social media amongst medical professionals has led to widespread use for both networking and education. Limited professional guidance exists on the sharing of medical imagery on these platforms. This Comment explores consent and offers reflective advice on the use of medical images on social media.

    • Jonathan P. Segal
    • Richard Hansen
    Comment
  • Intestinal ultrasonography (IUS) is an emerging, noninvasive, highly accessible and low-cost cross-sectional imaging modality for inflammatory bowel disease. This Comment summarizes how IUS in a point-of-care setting enables close patient monitoring.

    • Floris A. E. de Voogd
    • Bram Verstockt
    • Krisztina B. Gecse
    Comment
  • Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.

    • Ferdinando D’Amico
    • Christian Rabaud
    • Silvio Danese
    Comment
  • Progress towards hepatitis B virus (HBV) elimination targets remains slow, despite efforts to support enhanced prevention, diagnosis and treatment. On the basis of insights from interventions against HIV, we argue for the wider use of antiviral therapy for HBV, highlighting the potential public health benefits in preventing liver disease and reducing transmission.

    • Anna L. McNaughton
    • Maud Lemoine
    • Philippa C. Matthews
    Comment
  • Case reports and retrospective cohort studies have reported an association between acute pancreatitis and COVID-19. As SARS-CoV-2 (the causative agent of COVID-19) receptors are expressed in the pancreas and endothelial damage can occur, this association is plausible. However, this hypothesis has many biases and needs further investigation.

    • Enrique de-Madaria
    • Gabriele Capurso
    Comment
  • To therapeutically modulate gut microbial ecosystems, a better understanding of gut ecology is key. High-throughput in vitro ecology provides a tool with the necessary power to address these needs and interpersonal treatment response variation.

    • Emma Hernandez-Sanabria
    • Jorge Francisco Vázquez-Castellanos
    • Jeroen Raes
    Comment
  • Structural racism in academia and academic medicine is destructive to science and society. To deny its existence is to fertilize the soil in which it thrives. Uprooting it demands, at the very least, a fundamental transformation in institutional education, policies, practices and resource allocation with sustained anti-racist actions.

    • Darrell M. Gray II
    • Joshua J. Joseph
    • J. Nwando Olayiwola
    Comment
  • The effect of coronavirus disease 2019 (COVID-19) on liver transplantation programmes and recipients is still not completely understood but overall involves the risk of donor-derived transmission, the reliability of diagnostic tests, health-care resource utilization and the effect of immunosuppression. This Comment reviews the effect of COVID-19 on liver transplantation and summarizes recommendations for donor and recipient management.

    • Tommaso Di Maira
    • Marina Berenguer
    Comment
  • Data based on next-generation sequencing (NGS) of colorectal cancers (CRC) clearly show that up to 10% of all cases harbour pathogenic variants. Thus, NGS performed for all patients with CRC under the age of 50 could be a cost-effective strategy, leading to a personalized approach to patients and family members.

    • Luigi Laghi
    • Luigi Ricciardiello
    Comment
  • Deep learning can mine clinically useful information from histology. In gastrointestinal and liver cancer, such algorithms can predict survival and molecular alterations. Once pathology workflows are widely digitized, these methods could be used as inexpensive biomarkers. However, clinical translation requires training interdisciplinary researchers in both programming and clinical applications.

    • Jakob N. Kather
    • Julien Calderaro
    Comment
  • The gastrointestinal tract represents a target organ for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), warranting a thorough discussion on the consequences, particularly regarding inflammatory bowel diseases. Here, aspects of gastrointestinal involvement with SARS-CoV-2, the role of viruses as modulators of mucosal immunity and as treatment-related safety hazards, and the current clinical evidence will be discussed.

    • Alexander R. Moschen
    Comment
  • Greater than the coronavirus disease 2019 (COVID-19) crisis, systemic inequity in social determinants of health is the pandemic that has long fostered vulnerability to disease and poor health outcomes in the USA. Our response has major implications for the health of our nations.

    • Darrell M. Gray II
    • Adjoa Anyane-Yeboa
    • Folasade P. May
    Comment
  • Coronavirus disease 2019 (COVID-19) itself and/or the use of hepatotoxic drugs might negatively affect the course and management of patients with pre-existing chronic liver diseases. However, the greatest effect of COVID-19 on liver diseases will be indirect and delayed, resulting from the impending global economic crisis.

    • Jean-Michel Pawlotsky
    Comment
  • On ‘International NASH Day’, we launch a call for the global health community to collaboratively shape and deliver a comprehensive, long-term public health agenda for NAFLD. A global multidisciplinary coalition is needed to guide our response to this increasingly prevalent, yet underaddressed disease.

    • Jeffrey V. Lazarus
    • Massimo Colombo
    • Shira Zelber-Sagi
    Comment